Skip to content

Syngene to acquire plant from Stelis Biopharma for Rs 702 crore

The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.

Read More

​ The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday. The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish